Role and prognostic value of oncostatin M and its receptor OSMR in acute myeloid leukemia, myeloproliferative neoplasms and non-hematological malignancies.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2025-09-17 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1636570

Jean-Pierre Lévesque, Kavita Bisht, Kylie A Alexander, Ingrid G Winkler

引用次数: 0

Abstract

The oncostatin M receptor (OSMR) has recently emerged as an adverse prognostic factor in acute myeloid leukemia (AML) and several non-hematological malignancies. In this perspective, we discuss how oncostatin M (OSM) and its receptor OSMR regulate tumor cells as well as mesenchymal and endothelial cells, which are key components of hematopoietic stem cell and tumor stem cell niches, and how these mechanisms could explain the poor prognosis associated with high expression of OSM and OSMR in hematological and non-hematological malignancies.

查看原文本刊更多论文

肿瘤抑制素M及其受体OSMR在急性髓系白血病、骨髓增生性肿瘤及非血液系统恶性肿瘤中的作用及预后价值

肿瘤抑制素M受体（OSMR）最近被认为是急性髓性白血病（AML）和几种非血液系统恶性肿瘤的不良预后因素。从这个角度来看，我们讨论了肿瘤抑制素M （OSM）及其受体OSMR如何调节肿瘤细胞、间质细胞和内皮细胞，这些细胞是造血干细胞和肿瘤干细胞生态位的关键组成部分，以及这些机制如何解释血液和非血液恶性肿瘤中与OSM和OSMR高表达相关的不良预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.